Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MMP4 Antibodies:
Go to our pre-filtered search.
Human Monoclonal MMP4 Primary Antibody for IF, WB - ABIN968762
Buaas, Lee, Edelhoff, Disteche, Braun: Cloning and characterization of the mouse interleukin enhancer binding factor 3 (Ilf3) homolog in a screen for RNA binding proteins. in Mammalian genome : official journal of the International Mammalian Genome Society 1999
Show all 4 Pubmed References
Human Monoclonal MMP4 Primary Antibody for IF, WB - ABIN968761
Patel, Vestal, Xu, Bandyopadhyay, Guo, Erme, Williams, Sen: DRBP76, a double-stranded RNA-binding nuclear protein, is phosphorylated by the interferon-induced protein kinase, PKR. in The Journal of biological chemistry 1999
Show all 4 Pubmed References
Data support a model in which NF45 (show ILF2 Antibodies), NF90, and NF110 operate in feedback loops that enable them, through both overlapping and independent targets, to help balance the push and pull of pluripotency and differentiation cues.
Reduction in the expression of YBX1 (show YBX1 Antibodies) and ILF3 controls the expression of pluripotency-related genes in ESCs (show NR2E3 Antibodies), suggesting their roles in further regulation of the pluripotent state of ESCs (show NR2E3 Antibodies).
NF90-NF45 (show ILF2 Antibodies) complex induces centronuclear myopathy through increased dynamin 2 (show DNM2 Antibodies) expression by an NF90-NF45 (show ILF2 Antibodies)-induced reduction of miR (show MLXIP Antibodies)-133a expression in vivo.
This work allows to establish a link between Ilf3 and NF90 functions, as RNA binding proteins, and their interacting partners implicated in these functions.
High expression of nuclear factor 90 leads to mitochondrial degradation in skeletal and cardiac muscles through a negative regulation of ribosomes via interaction with ribosomal factors.
cloning of human NF90
characterization of NFAR-1 and NFAR-2 splice forms in human sample
NF90 regulates cell cycle exit and terminal myogenic differentiation by direct binding to the 3'-untranslated region of MyoD (show MYOD1 Antibodies) and p21WAF1/CIP1 mRNAs
ADAR1 (show ADAR Antibodies) has the potential both to change information content through editing of mRNA and to regulate gene expression through interacting with NF90
NF90 regulates inducible IL-2 (show IL2 Antibodies) gene expression in T cells.
Studies suggest a two-component model for the binding of CBTF with gata2 (show GATA2 Antibodies) promoter, requiring both a CCAAT and A-form DNA, and the double stranded RNA binding domains (dsRBDs) of CBTF component Xilf3 must be active for both binding to the promoter.
Reprot a coordinated regulation of circRNA biogenesis and function by NF90/NF110 in viral infection.
The NF90 regulates PARP1 (show PARP1 Antibodies) mRNA stability in hepatocellular carcinoma cells, and NF90 is a potential target to inhibit PARP1 (show PARP1 Antibodies) activity.
Variants in ILF3 gene is associated with thrombosis.
these data establish miR (show MLXIP Antibodies)-590-5p as an anti-onco-miR (show MLXIP Antibodies) that inhibits colorectal cancer angiogenesis and metastasis through a new mechanism involving NF90/VEGFA (show VEGFA Antibodies) signaling axis.
The data suggest that features of both the N- and C-termini of NF90 participate in the heterodimerization with NF45 (show ILF2 Antibodies) and that the formation of NF90-NF45 (show ILF2 Antibodies) changes the conformation of NF90's RNA-binding motifs to a status in which the co-operative interplay of the RNA-binding motifs is optimal.
NF90-NF45 (show ILF2 Antibodies) stimulates an elevation of EGF receptor (show EGFR Antibodies) levels via the suppression of miR-7 (show LILRB1 Antibodies) biogenesis, resulting in the promotion of cell proliferation in Hepatocellular Carcinoma.
NF90 exerts its antiviral activity by antagonizing the inhibitory role of NS1 (show PTPN11 Antibodies) on PKR (show PKLR Antibodies) phosphorylation
Deletion of the RNA binding domains of NF45 (show ILF2 Antibodies) and NF90 diminished the enhancement of HIV infection and gene expression.
These data suggest that, like ADAR2 (show ADARB1 Antibodies), underlying sequences in dsRNA may influence how NF90 recognizes its target RNAs
The NF90 C-terminus is involved in conformational changes in the protein after RNA binding.
This gene encodes a double-stranded RNA (dsRNA) binding protein that complexes with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene expression and stabilize mRNAs. This protein was first discovered to be a subunit of the nuclear factor of activated T-cells (NFAT)\; a transcription factor required for T-cell expression of interleukin 2. NFAT is a heterodimer of 45 kDa and 90 kDa proteins, the larger of which is the product of this gene. These proteins have been shown to affect the redistribution of nuclear mRNA to the cytoplasm. Knockdown of NF45 or NF90 protein retards cell growth\; possibly by inhibition of mRNA stabilization. In contrast, an isoform (NF110) of this gene that is predominantly restricted to the nucleus has only minor effects on cell growth when its levels are reduced. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
M phase phosphoprotein 4
, interleukin enhancer-binding factor 3
, nuclear factor 90
, nuclear factor associated with dsRNA
, CCAAT box transcription factor p122 subunit
, CCAAT box transcription factor subunit
, Double-stranded RNA-binding protein 4F.1
, dsRNA-binding protein 4F.1
, interleukin enhancer-binding factor 3-A
, M-phase phosphoprotein 4
, double-stranded RNA-binding protein, 76 kD
, dsRNA binding protein NFAR-2/MPP4
, nuclear factor of activated T-cells 90 kDa
, nuclear factor of activated T-cells, 90 kD
, translational control protein 80
, interleukin enhancer binding factor 3, 90kDa
, interleukin enhancer-binding factor 3 homolog